Insurance coverage, physician recommendations, and access to emerging treatments: Growth hormone therapy for childhood short stature

JAMA

Volumn 279, Issue 9, 1998, Pages 663-668

  Finkelstein, Beth S ^a   Silvers, J B ^b   Marrero, Ursula ^a   Neuhauser, Duncan ^a   Cuttler, Leona ^a,c  

^a Alzheimer Research Laboratory   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ARTICLE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HORMONAL THERAPY; MEDICAL DECISION MAKING; PHYSICIAN; POLICY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SHORT STATURE; TREATMENT INDICATION;

EID: 0032481596     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.9.663     Document Type: Article

References (37)

1. Hadley J, Steinberg EP, Feder J. Comparison of uninsured and privately insured hospital patients: condition on admission, resource use, and outcome. JAMA 1991;265:374-379.
2. Light DW. Life, death, and the insurance companies. N Engl J Med. 1994;330:498-500.
3. Aday LA, Eun SL, Spears B, Chih-Wen C, Youssef A, Bloom B. Health insurance and utilization of medical care for children with special health care needs. Med Care. 1993;31:1013-1026.
4. Lippe BM, Nakamoto JM. Conventional and nonconventional uses of growth hormone. Recent Prog Horm Res. 1993;48:179-235.
5. Cuttler L, Silvers JB, Singh J, et al. Short stature and growth hormone therapy: a national study of physician recommendation patterns. JAMA. 1996; 276:531-537.
6. Abramowicz M. Recombinant human growth hormone. Med Lett Drugs Ther. 1994;36:77-78.
7. Furlanetto RW, and the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature. J Pediatr. 1995; 127:857-867.
8. American Academy of Pediatrics, Committee on Drugs and Committee on Bioethics. Conditions related to the use of recombinant human growth hormone in children. Pediatrics. 1997;99:122-129.
9. Wit JM. Growth disorders in children: diagnostic and therapeutic dilemmas. Endocr News. 1997;22:1.
10. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab. 1995;80:1532-1540.
11. Lantos J, Siegler M, Cuttler L. Ethical issues in growth hormone therapy. JAMA. 1989;261:1020-1024.
12. Underwood LE. Growth hormone therapy for short stature: yes or no? Hosp Pract. 1992;27:192-198.
13. Rosenfield R, Cara J. Somatic growth and maturation. In: DeGroot L, ed. Endocrinology. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1995:2549-2589.
14. Rosenfeld RG, Tesch LG, Rodriguez-Rigau LJ, McCauley E, Albertsson-Wikland K, Asch R. Recommendations for diagnosis, treatment, and management of individuals with Turner syndrome. Endocrinologist. 1994;4:351-358.
15. Wyatt DT, Mark D, Slyper A. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab. 1995;80: 3292-3297.
16. Tanner JM, Davies PSW. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329.
17. Moore KC, Donaldson DL, Ideus PL, Gifford RA, Moore WV. Clinical diagnosis of children with extremely short stature and their response to growth hormone. J Pediatr. 1993;122:687-692.
18. Singh J, Cuttler L, Shin M, Silvers JB, Neuhauser D. Medical decision making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. Med Care. In press.
19. Moore KG. A survey of state Medicaid policies for coverage of screening mammography and Pap smear services. Womens Health Issues. 1992;2:40-49.
20. Newacheck PW, McManus MA. Financing health care for disabled children. Pediatrics. 1988; 81:385-394.
21. American Medical Association, Department of Data Survey & Planning, Division of Survey and Data Resources. Physician Characteristics and Distribution in the United States 1995. Chicago, Ill: American Medical Association: 1995:Table A-20.
22. Salmon JW. A perspective on the corporate transformation of health care. Int J Health Serv. 1995;25:11-42.
23. Group Health Association of America. 1993 HMO National Directory 3rd ed. Washington, DC: Group Health Association of America; 1993.
24. US Dept of Commerce. Statistical Abstract of the United States 1993. 113th ed. Washington, DC: Bureau of the Census; 1995:118.
25. Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW. Prevalence of severe growth hormone deficiency. BMJ. 1977;2:427-430.
26. United States Renal Data System. USRDS 1995 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1995:B11.
27. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technique. N Engl J Med. 1973;88:1272-1275.
28. Newacheck PW, Hughes DC, Cisternas M. Children and health insurance: an overview of recent trends. Health Aff (Millwood). 1995;14:244-254.
29. Lewit EM, Baker Shuurmann L. Health insurance coverage. Future Child. 1995;5:192-204.
30. Congressional Research Service. Medicaid Source Book: Background Data and Analysis. Washington, DC: US Government Printing Office; 1993:Table A-13.
31. Buchanan RJ, Smith SR. Medicaid policies for HIV-related drug therapies: perspectives of the state affiliates of the American Pharmaceutical Association. Pharmacoeconomics. 1994;28:528-535.
32. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med. 1994;330:473-477.
33. Steiner CM, Powe NR, Anderson GF, Das A. The review process used by U.S. health care plans to evaluate new medical technology for coverage. J Gen Intern Med. 1996;11:294-302.
34. Hall MA, Anderson GF. Health insurer's assessment of medical necessity. University Pa Law Rev. 1992;140:1637-1661.
35. Rosenthal E. Patients with rare illnesses fight new H.M.O.'s to get treatment. New York Times. July 15, 1996:A1, A7. Midwest edition.
36. O'Conner M. Court is battlefield in cancer fight for life. Chicago Tribune. July 22, 1995;section 1:5.
37. Agency for Health Care Policy and Research and the National Institute for Health Care Management. Medical Necessity: A Symposium on Policy Issues, Implementation Challenges and Tough Choices, Proceedings, Washington D.C., April 28, 1995. Washington, DC: Agency for Health Care Policy and Research; 1995.